Zhengda Qingjiang's anti-inflammatory drug "Selaxib capsule" through the consistency evaluation.

It is reported that seloxib is a selective cyclooxidase-2 (COX-2) inhibitor nonsteroidal anti-inflammatory drug, used to relieve the symptoms and symptoms of osteoarthritis, relieve the symptoms and symptoms of rheumatoid arthritis into humanr, treatment of acute pain in adults and so on.
sales of Cirxiosib capsules at the terminals of public medical institutions in China (units: 10,000 yuan)
-meter net data show that in 2018 sales of Chinese urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) exceeded 1 billion yuan, up 25.28 percent year-on-year.

before that, manufacturers included Pfizer and Hennessy.
China Biopharmaceuticals said the approval of Selaxib Capsules will further enrich the Group's product portfolio and contribute to the Group's development in the field of orthopaedic medicine.

consistency evaluation, Hengrui and Zhengda Qingjiang are approved by imitation 4 categories of declaration, as if the same through consistency evaluation.
Source: Announcement of Listed Companies, Minnet Database Original Title: "Challenge" Pfizer, Heng Rui! Zhengda Qingjiang into the bureau 1 billion anti-inflammatory drugs.